Arvinas (NASDAQ:ARVN) CEO Randy Teel Sells 4,403 Shares

Arvinas, Inc. (NASDAQ:ARVN) CEO Randy Teel sold 4,403 shares of Arvinas stock in a transaction that occurred on Friday, February 13th. The stock was sold at an average price of $11.89, for a total transaction of $52,351.67. Following the transaction, the chief executive officer directly owned 154,482 shares in the company, valued at $1,836,790.98. This trade represents a 2.77% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink.

Arvinas Stock Up 3.3%

Shares of Arvinas stock traded up $0.38 during trading on Wednesday, reaching $11.82. The company’s stock had a trading volume of 559,743 shares, compared to its average volume of 759,739. Arvinas, Inc. has a 52-week low of $5.90 and a 52-week high of $19.40. The firm’s 50-day moving average is $12.40 and its two-hundred day moving average is $10.32. The company has a market cap of $759.13 million, a price-to-earnings ratio of -14.59 and a beta of 1.88.

Analyst Upgrades and Downgrades

Several research analysts have recently commented on the company. Weiss Ratings reiterated a “sell (d-)” rating on shares of Arvinas in a report on Monday, December 22nd. Stephens raised their price target on Arvinas from $14.00 to $15.00 and gave the stock an “overweight” rating in a research report on Monday, November 10th. Barclays boosted their price objective on shares of Arvinas from $16.00 to $18.00 and gave the company an “overweight” rating in a research report on Wednesday, December 17th. Wells Fargo & Company cut their price objective on Arvinas from $16.00 to $15.00 and set an “overweight” rating on the stock in a research report on Thursday, November 6th. Finally, BTIG Research upped their target price on Arvinas from $10.00 to $14.00 and gave the company a “buy” rating in a report on Thursday, October 30th. Ten investment analysts have rated the stock with a Buy rating, eight have issued a Hold rating and two have issued a Sell rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of “Hold” and an average target price of $13.12.

Institutional Investors Weigh In On Arvinas

Several institutional investors and hedge funds have recently made changes to their positions in ARVN. AQR Capital Management LLC purchased a new position in Arvinas in the 1st quarter worth approximately $727,000. Jacobs Levy Equity Management Inc. bought a new position in Arvinas during the 1st quarter valued at about $301,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its holdings in shares of Arvinas by 5.8% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 38,636 shares of the company’s stock valued at $271,000 after acquiring an additional 2,122 shares during the last quarter. Millennium Management LLC grew its stake in shares of Arvinas by 208.4% in the first quarter. Millennium Management LLC now owns 1,310,326 shares of the company’s stock worth $9,198,000 after acquiring an additional 885,483 shares during the period. Finally, UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC raised its holdings in shares of Arvinas by 108.3% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 902,925 shares of the company’s stock valued at $6,339,000 after purchasing an additional 469,394 shares during the last quarter. Institutional investors own 95.19% of the company’s stock.

About Arvinas

Arvinas, Inc (NASDAQ: ARVN) is a biopharmaceutical company focused on the development of therapies based on targeted protein degradation. Utilizing its proprietary proteolysis-targeting chimera (PROTAC®) platform, Arvinas aims to selectively eliminate disease-causing proteins rather than merely inhibit their activity. This novel approach has the potential to address a range of diseases, including oncology, neurodegeneration and inflammation, by harnessing the body’s natural protein-recycling systems.

The company’s most advanced clinical candidates address hormone-driven cancers.